Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hypersensitivity Reactions: Immune-Complex Reactions01:19

Hypersensitivity Reactions: Immune-Complex Reactions

218
Type III hypersensitivity reactions occur when antigen–antibody complexes form and activate the complement system. Normally, these complexes help the clearance of antigens by phagocytes and red blood cells. However, when large numbers of immune complexes are present, they can deposit in tissues—particularly in the walls of blood vessels—leading to inflammation and tissue injury. These deposits trigger complement activation and neutrophil recruitment, resulting in serum...
218
Transcytosis of IgG01:15

Transcytosis of IgG

4.6K
Transcytosis is the process in which molecules are internalized by endocytosis, transported across the cell, and released through exocytosis from the opposite end of the cell. Molecules such as insulin, immunoglobulins, and certain nutrients are transferred through the recycling endosomes by recycling and transcytosis.
IgG molecules from a mother undergo transcytosis starting around 13 weeks of gestation. The amount of IgG transferred and entering the fetal blood circulation increases with...
4.6K
Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

1.1K
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
1.1K
Blood Transfusion and Agglutination02:45

Blood Transfusion and Agglutination

16.1K
Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
16.1K
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

367
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
367
Hypersensitivity Reactions: Cytolytic Reactions01:01

Hypersensitivity Reactions: Cytolytic Reactions

157
Type II hypersensitivity involves IgG and IgM antibodies targeting cell surface antigens, leading to cell destruction. This can occur through complement activation, antibody-dependent cell-mediated cytotoxicity (ADCC), or acting as opsonins for phagocytosis. When excessive, these reactions cause significant tissue damage.Drug-induced hemolytic anemia is a common example, where drugs like penicillin or cephalosporins bind to red blood cells, forming drug-protein complexes. These complexes...
157

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term outcomes and prognosis of mixed cryoglobulinaemia: a European multicentre study of 1294 patients.

Rheumatology (Oxford, England)·2026
Same author

Treat-to-target in Behçet syndrome.

Nature reviews. Rheumatology·2026
Same author

French recommendations for the use of imaging in giant cell arteritis.

Joint bone spine·2026
Same author

Clonal haematopoiesis of indeterminate potential and relapses in patients with GCA.

Rheumatology (Oxford, England)·2026
Same author

Takayasu arteritis phenotypes and outcomes: A data-driven cluster analysis from a large international cohort.

Journal of autoimmunity·2026
Same author

When to suspect monogenic autoinflammatory diseases in patients with digestive symptoms?

Clinics and research in hepatology and gastroenterology·2026
Same journal

Mineralocorticoid Antagonists for Post-MI HFpEF: Plausible Biology Meets Low Residual Risk?

The American journal of medicine·2026
Same journal

GLP-1 Receptor Agonists and Age-related Macular Degeneration Risk in Diabetes or Non-diabetic Obesity: A Retrospective Cohort Study.

The American journal of medicine·2026
Same journal

Marijuana Use and Acute Myocardial Infarction: Mechanistic Insights, Clinical Implications, and Emerging Challenges.

The American journal of medicine·2026
Same journal

Cave Canem - Beware of the Dog.

The American journal of medicine·2026
Same journal

Risk Factors for 30-day Hospital Readmission After Hospital-at-Home Treatment of Acute Pyelonephritis.

The American journal of medicine·2026
Same journal

Mesenteric panniculitis.

The American journal of medicine·2026
See all related articles

Related Experiment Video

Updated: Apr 15, 2026

Granulocyte-dependent Autoantibody-induced Skin Blistering
12:23

Granulocyte-dependent Autoantibody-induced Skin Blistering

Published on: October 12, 2012

11.0K

Cryoglobulinemia Vasculitis.

Patrice Cacoub1, Cloe Comarmond1, Fanny Domont2

  • 1Sorbonne Universités, University Pierre and Marie Curie (UPMC), UMR 7211, and Inflammation-Immunopathology-Biotherapy Department (DHU i2B), Paris, France; Institute National de la Santé et de la Recherche Medicalé (INSERM), UMR_S 959, Paris, France; Centre National de la Recherche Scientifique (CNRS), FRE3632, Paris, France; Department of Internal Medicine and Clinical Immunology, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.

The American Journal of Medicine
|April 4, 2015
PubMed
Summary
This summary is machine-generated.

Cryoglobulinemic vasculitis (CryoVas) impacts skin, joints, nerves, and kidneys. Treatment effectiveness varies by type and cause, with antivirals improving outcomes in Hepatitis C-related cases.

Keywords:
Cryoglobulinemia vasculitisCryoglobulinsHCVPrognosisTreatment

More Related Videos

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

7.9K
Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis
10:27

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis

Published on: December 15, 2011

25.1K

Related Experiment Videos

Last Updated: Apr 15, 2026

Granulocyte-dependent Autoantibody-induced Skin Blistering
12:23

Granulocyte-dependent Autoantibody-induced Skin Blistering

Published on: October 12, 2012

11.0K
An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

7.9K
Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis
10:27

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis

Published on: December 15, 2011

25.1K

Area of Science:

  • Immunology
  • Rheumatology
  • Nephrology

Background:

  • Cryoglobulinemic vasculitis (CryoVas) is a small-vessel vasculitis affecting multiple organs.
  • Type I CryoVas involves monoclonal immunoglobulins linked to B-cell disorders.
  • Mixed cryoglobulinemia (Types II and III) involves polyclonal IgG, often with rheumatoid factor activity, frequently associated with Hepatitis C virus (HCV) infection.

Purpose of the Study:

  • To review the classification, causes, prognostic factors, and treatment strategies for Cryoglobulinemic vasculitis.
  • To highlight the distinct outcomes and management approaches for Type I and mixed CryoVas, particularly in relation to HCV infection.

Main Methods:

  • Review of existing literature on Cryoglobulinemic vasculitis.
  • Analysis of survival rates and prognostic factors based on CryoVas type and etiology (HCV-positive vs. HCV-negative).
  • Summary of current treatment recommendations, including antivirals, immunosuppressants, and targeted therapies like rituximab.

Main Results:

  • 10-year survival rates differ significantly: 87% for Type I, 65% for HCV-negative mixed CryoVas, and 63% for HCV-positive mixed CryoVas.
  • Poor prognostic factors in HCV-positive patients include severe liver fibrosis and organ involvement (CNS, kidney, heart). Antiviral treatment improves prognosis.
  • In HCV-negative patients, poor prognostic factors include pulmonary/gastrointestinal involvement, renal insufficiency, and age > 65. Lymphoma risk is increased.
  • Treatment for Type I CryoVas targets the underlying hemopathy, with options like plasma exchange, corticosteroids, and rituximab.
  • HCV-CryoVas management involves antivirals for mild disease. Severe cases require disease control with rituximab +/- plasmapheresis before antiviral therapy. Immunosuppressants are reserved for refractory cases or lymphoma.

Conclusions:

  • Prognosis and treatment of CryoVas are highly dependent on the type of cryoglobulin and the presence of HCV infection.
  • Early and appropriate treatment, particularly antiviral therapy for HCV-related CryoVas, is crucial for improving patient outcomes.
  • Risk stratification based on clinical presentation and prognostic factors guides therapeutic decisions, emphasizing targeted therapies for severe or refractory disease.